Increased mortality after dronedarone therapy for severe heart failure.
By L. Køber, C. Torp-Pedersen, J. McMurray, O. Gøtzsche, S. Lévy, H. Crijns, J. Amlie, J. Carlsen. New England Journal of Medicine, 2008
934 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine
View Paper: https://www.semanticscholar.org/paper/db95650b5511838f59f25b3831ebc213cf56e8ff
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
- G. Fonarow
- Gerhard Hindricks
- T. Horwich
- M. Ezekowitz
- Gregory Y. H. Lip
- A. Goette
- Paulus Kirchhof
- Ulrich Schotten
Citations in the corpus
- 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. (2013, background): “Diagnosis or exclusion of HF Acute I A (212, 217-223, 245-250)”
- 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. (2014, positive): “Dronedarone should not be used to control the ventricular rate in patients with permanent AF as it increases the risk of the combined endpoint of stroke, MI, systemic embolism, or cardiovascular death (108, 109).”
- Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). (2010, methodology): “Dronedarone is contraindicated in patients with NYHA class III– IV or recently (within the previous 4 weeks) decompensated heart failure.(117) In such patients, amiodarone should be used.”
- 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure (2016, neutral): “Other antiarrhythmic drugs should be avoided.(247) Transcatheter radiofrequency modification of the arrhythmogenic substrate may reduce the number of appropriate ICD discharges and may be used to terminate arrhythmic storm in patients with Recommendations for the prevention of thrombo-embolism in pa”